Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

The effect of left atrial appendage closure on heart failure biomarkers: A PRAGUE-17 trial subanalysis

D. Herman, P. Osmancik, P. Neuzil, P. Hala, V. Lekesova, K. Benesova, M. Hozman, J. Jarkovsky, M. Novackova, P. Widimsky, VY. Reddy, PRAGUE-17 Trial Investigators

. 2021 ; 32 (10) : 2645-2654. [pub] 20210826

Language English Country United States

Document type Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

INTRODUCTION: The randomized PRAGUE-17 trial demonstrated noninferiority of left atrial appendage closure (LAAC) to non-vitamin K anticoagulants (NOACs) for the prevention of major cardiovascular or cerebrovascular events. However, the left atrial appendage is an important source of natriuretic peptides and plays a role in left atrial reservoir function. Changes of heart failure (HF) biomarkers after LAAC compared to NOAC has not been studied. The aim of the study was to compare the changes in concentrations of HF biomarkers between LAAC and NOAC patients. METHODS: Of 402 patients randomized in the PRAGUE-17 trial, biomarkers were analyzed in 144 patients (73 in the NOAC and 71 in the LAAC group). Both groups had similar baseline characteristics. Serum concentration of NT-proBNP, NT-proANP, Galectin-3, and GDF-15 were measured at baseline (before the procedure in the LAAC group), at the 6-month (and at 24-month for NT-proBNP) follow-up timepoint. RESULTS: There were no significant differences in baseline, 6 month, and delta (δ = baseline - 6 month) concentrations of NT-proANP between the groups (NOAC: baseline 2.6 [0.5; 4.9], 6-month 3.1 [1.8; 4.8], p = .068; LAAC: baseline 3.3 [1.1; 4.6], 6-month 2.6 [0.9; 5.3], p = .51; p value for δ in concentrations between groups = 0.42). Similarly, there were no significant differences in baseline, 6, 24 months, and delta concentrations of NT-proBNP between the groups (NOAC: baseline 461.0 [113.5; 1342.0], 6 month 440.0 [120.5; 1291.5], 24 month 798 [274; 2236], p = .39; LAAC: baseline 421.0 [100.0; 1320.0], 6 month 601.0 [145.0; 1230.0], 24 month 855 [410; 1367], p = .28; p value for δ in concentrations between groups = 0.73 at 6 months, and 0.58 at 24 months). Finally, no significant differences were present in baseline, 6 month, and δ concentrations of Galectin-3 and GDF-15 between the two groups. CONCLUSION: LAAC did not significantly influence the levels of HF biomarkers 6 months after the procedure.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003599
003      
CZ-PrNML
005      
20220127150053.0
007      
ta
008      
220113s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1111/jce.15206 $2 doi
035    __
$a (PubMed)34402135
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Herman, Dalibor $u Department of Cardiology, Third Faculty of Medicine, University Hospital Kralovske Vinohrady, Charles University Prague, Prague, Czech Republic
245    14
$a The effect of left atrial appendage closure on heart failure biomarkers: A PRAGUE-17 trial subanalysis / $c D. Herman, P. Osmancik, P. Neuzil, P. Hala, V. Lekesova, K. Benesova, M. Hozman, J. Jarkovsky, M. Novackova, P. Widimsky, VY. Reddy, PRAGUE-17 Trial Investigators
520    9_
$a INTRODUCTION: The randomized PRAGUE-17 trial demonstrated noninferiority of left atrial appendage closure (LAAC) to non-vitamin K anticoagulants (NOACs) for the prevention of major cardiovascular or cerebrovascular events. However, the left atrial appendage is an important source of natriuretic peptides and plays a role in left atrial reservoir function. Changes of heart failure (HF) biomarkers after LAAC compared to NOAC has not been studied. The aim of the study was to compare the changes in concentrations of HF biomarkers between LAAC and NOAC patients. METHODS: Of 402 patients randomized in the PRAGUE-17 trial, biomarkers were analyzed in 144 patients (73 in the NOAC and 71 in the LAAC group). Both groups had similar baseline characteristics. Serum concentration of NT-proBNP, NT-proANP, Galectin-3, and GDF-15 were measured at baseline (before the procedure in the LAAC group), at the 6-month (and at 24-month for NT-proBNP) follow-up timepoint. RESULTS: There were no significant differences in baseline, 6 month, and delta (δ = baseline - 6 month) concentrations of NT-proANP between the groups (NOAC: baseline 2.6 [0.5; 4.9], 6-month 3.1 [1.8; 4.8], p = .068; LAAC: baseline 3.3 [1.1; 4.6], 6-month 2.6 [0.9; 5.3], p = .51; p value for δ in concentrations between groups = 0.42). Similarly, there were no significant differences in baseline, 6, 24 months, and delta concentrations of NT-proBNP between the groups (NOAC: baseline 461.0 [113.5; 1342.0], 6 month 440.0 [120.5; 1291.5], 24 month 798 [274; 2236], p = .39; LAAC: baseline 421.0 [100.0; 1320.0], 6 month 601.0 [145.0; 1230.0], 24 month 855 [410; 1367], p = .28; p value for δ in concentrations between groups = 0.73 at 6 months, and 0.58 at 24 months). Finally, no significant differences were present in baseline, 6 month, and δ concentrations of Galectin-3 and GDF-15 between the two groups. CONCLUSION: LAAC did not significantly influence the levels of HF biomarkers 6 months after the procedure.
650    _2
$a aplikace orální $7 D000284
650    _2
$a antikoagulancia $x terapeutické užití $7 D000925
650    12
$a síňové ouško $x diagnostické zobrazování $x chirurgie $7 D020517
650    12
$a fibrilace síní $x diagnóza $x farmakoterapie $x chirurgie $7 D001281
650    _2
$a biologické markery $7 D015415
650    12
$a srdeční selhání $x diagnóza $x farmakoterapie $7 D006333
650    _2
$a lidé $7 D006801
650    12
$a cévní mozková příhoda $7 D020521
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Osmancik, Pavel $u Department of Cardiology, Third Faculty of Medicine, University Hospital Kralovske Vinohrady, Charles University Prague, Prague, Czech Republic
700    1_
$a Neuzil, Petr $u Cardiocenter, Department of Cardiology, Na Homolce Hospital, Prague, Czech Republic
700    1_
$a Hala, Pavel $u Cardiocenter, Department of Cardiology, Na Homolce Hospital, Prague, Czech Republic
700    1_
$a Lekesova, Veronika $u Cardiocenter, Department of Cardiology, Na Homolce Hospital, Prague, Czech Republic
700    1_
$a Benesova, Klara $u Department of Data Analysis, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
700    1_
$a Hozman, Marek $u Cardiocenter, Karlovy Vary Regional Hospital, Karlovy Vary, Czech Republic
700    1_
$a Jarkovsky, Jiri $u Department of Data Analysis, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
700    1_
$a Novackova, Martina $u Department of Data Analysis, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
700    1_
$a Widimsky, Petr $u Department of Cardiology, Third Faculty of Medicine, University Hospital Kralovske Vinohrady, Charles University Prague, Prague, Czech Republic
700    1_
$a Reddy, Vivek Y $u Cardiocenter, Department of Cardiology, Na Homolce Hospital, Prague, Czech Republic $u Department of Electrophysiology, Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA
710    2_
$a PRAGUE-17 Trial Investigators
773    0_
$w MED00002569 $t Journal of cardiovascular electrophysiology $x 1540-8167 $g Roč. 32, č. 10 (2021), s. 2645-2654
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34402135 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127150050 $b ABA008
999    __
$a ok $b bmc $g 1751153 $s 1154748
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 32 $c 10 $d 2645-2654 $e 20210826 $i 1540-8167 $m Journal of cardiovascular electrophysiology $n J Cardiovasc Electrophysiol $x MED00002569
LZP    __
$a Pubmed-20220113

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...